Discontinued — last reported Q1 '26
Vaxneuvance — Sales
Merck & Co. Vaxneuvance — Sales decreased by 27.9% to $202.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 56.2%, from $461.00M to $202.00M. Over 4 years (FY 2021 to FY 2025), Vaxneuvance — Sales shows an upward trend with a 307.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, expanded clinical adoption, or effective commercial execution, while a decrease may signal increased competition, pricing pressure, or loss of market share.
Detailed definition
This metric represents the total annual revenue generated from the sale of the pneumococcal conjugate vaccine product li...
Peer comparison
Comparable to revenue metrics for specific blockbuster vaccines or specialized pharmaceutical product lines at peer biotechnology and pharmaceutical companies.
mrk_segment_vaxneuvance_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.50M | $1.50M | $1.50M | $10.00M | $23.00M | $32.00M | $275.00M | $213.00M | $335.00M | $429.00M | $352.00M | $438.00M | $378.00M | $479.00M | $321.00M | $461.00M | $458.00M | $451.00M | $280.00M | $202.00M |
| QoQ Change | — | +0.0% | +0.0% | +566.7% | +130.0% | +39.1% | +759.4% | -22.5% | +57.3% | +28.1% | -17.9% | +24.4% | -13.7% | +26.7% | -33.0% | +43.6% | -0.7% | -1.5% | -37.9% | -27.9% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | >999% | >999% | +28.0% | +105.6% | +12.8% | +11.7% | -8.8% | +5.3% | +21.2% | -5.8% | -12.8% | -56.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s vaxneuvance — sales?
- Merck & Co. (MRK) reported vaxneuvance — sales of $202.00M in Q1 2026.
- How has Merck & Co.'s vaxneuvance — sales changed year-over-year?
- Merck & Co.'s vaxneuvance — sales decreased by 56.2% year-over-year, from $461.00M to $202.00M.
- What is the long-term trend for Merck & Co.'s vaxneuvance — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s vaxneuvance — sales has grown at a 307.2% compound annual growth rate (CAGR), from $6.00M to $1.65B.
- What does vaxneuvance — sales mean?
- The total annual revenue generated from the sales of the Vaxneuvance vaccine product line.